Bio-Rad Laboratories, Inc. Press Releases

BIO/B 
$117.57
*  
unch
unch
Get BIO/B Alerts
*Delayed - data as of Jul. 25, 2014  -  Find a broker to begin trading BIO/B now
Exchange: NYSE
Industry: Capital Goods
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By

Bio-Rad Announces the Appointment of New Board Member
7/25/2014 4:15:00 PM - Market Wire

BioAlliance Pharma: Approval of Onxeo’s admission to secondary listing and trading on NASDAQ OMX Copenhagen
7/24/2014 11:34:00 AM - Business Wire

The cross-border merger of BioAlliance Pharma and Topotarget is legally effective as of 22 July 2014
7/23/2014 2:00:00 PM - Business Wire

BioAlliance Pharma Announces the Launch of Sitavig® in the United States by Its Partner Innocutis
7/21/2014 2:00:00 PM - Business Wire

BioAlliance Pharma Strengthens Its Financial Resources with the Support of Its Top Shareholder
7/18/2014 11:45:00 AM - Business Wire

Bio-Rad to Report Second-Quarter 2014 Financial Results Tuesday, August 5, 2014
7/7/2014 5:30:00 PM - Market Wire

BioAlliance Pharma: FDA approval of Beleodaq™ (belinostat)
7/3/2014 1:58:00 PM - Business Wire

Bioalliance Pharma and Topotarget Shareholders Approve Proposed Cross-Border Merger to Create Onxeo
6/30/2014 12:30:00 PM - Business Wire

Bio-Rad Launches Vitamin D Kit for Its BioPlex 2200 System
6/23/2014 4:15:00 PM - Market Wire

Bio-Rad Launches the First Fully-Automated 5th Generation HIV Test
6/17/2014 6:24:00 PM - Market Wire

BioAlliance Pharma Strengthens Livatag® pAtent Protection in Japan Until 2032
6/10/2014 12:15:00 PM - Business Wire

Definitive Merger Plan between BioAlliance Pharma and Topotarget
5/21/2014 4:30:00 PM - Business Wire

BioAlliance Pharma SA: Livatag® Receives Fast Track Designation From the FDA for the Treatment of Primary Liver Cancer
5/19/2014 12:30:00 PM - Business Wire

Bio-Rad Reports First-Quarter 2014 Financial Results
5/6/2014 4:15:00 PM - Market Wire

BioAlliance Pharma SA: Quarterly information as of March 31, 2014
4/30/2014 2:09:00 PM - Business Wire

BioAlliance Pharma Publishes Its First Shareholder Newsletter
4/29/2014 3:00:00 PM - Business Wire

Bio-Rad Named One of the '2014 Best Places to Work in the Bay Area'
4/28/2014 4:05:00 PM - Market Wire